Developer docs
API playgroundTry for free, no card

Search company profiles

Cloudbreak Pharma

Full company profile

uuid0002lda

Namestring
Cloudbreak Pharma
Legal namestring
Cloudbreak Pharma, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Cloudbreak Pharma, Inc. is a clinical-stage ophthalmology biotechnology company founded in 2015 and headquartered in Irvine, California, with a regional office in Hong Kong and a listing on the Hong Kong Stock Exchange (HKEX: 2592). The company is developing a pipeline of first-in-class and best-in-class ophthalmic drugs targeting diseases with no FDA-approved pharmacological therapies, including pterygium, vascularized pinguecula, juvenile myopia, and presbyopia. As of mid-2025 it had four clinical-stage candidates — CBT-001 (nintedanib-based multi-kinase inhibitor eye drop for pterygium, Phase 3), CBT-004 (MKI eye drop for pinguecula, Phase 2 complete with Phase 3 readiness), CBT-009 (non-aqueous atropine for juvenile myopia, Phase 3), and CBT-199 (pupil-constricting formulation for presbyopia) — supported by four pre-clinical programs.

The company's scientific differentiation rests on two proprietary platforms: a Multi-Kinase Inhibitor (MKI) platform that simultaneously targets VEGFR, PDGFR, and FGFR to inhibit the angiogenesis and fibrosis driving pterygium and pinguecula; and a Semi-Fluorinated Alkanes (SFA+) drug-delivery platform providing non-aqueous, preservative-free formulations with improved stability and bioavailability for assets such as CBT-009 and CBT-199. The SFA+ carrier system directly addresses the long-standing stability limitation of aqueous low-dose atropine products.

Cloudbreak is pre-commercial and currently monetizes through regional licensing agreements rather than direct sales. In August 2024 it signed a licensing deal with Santen Pharmaceutical for CBT-001 across Japan and seven other Asia Pacific markets, worth up to US$91 million in upfront and milestone payments plus double-digit royalties on net sales. A 2020 agreement with Grand Pharmaceutical Group grants exclusive Greater China commercialization rights for CBT-001. The company is preparing for direct U.S. commercialization, evidenced by a new U.S. website launched in April 2026, appointment of Michael Rowe as Chief Business Officer in December 2025, and an experienced commercial leadership bench drawn from Allergan, Santen, Pfizer, Bayer, and Eyenovia.

Short descriptiontext

Cloudbreak Pharma is a clinical-stage ophthalmology biotech developing first-in-class eye drops for pterygium, pinguecula, myopia, and presbyopia using proprietary multi-kinase inhibitor and SFA+ delivery platforms, monetizing via regional licensing with Santen and Grand Pharmaceutical pending FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, biotechnology drug development, clinical-stage therapeutics, ophthalmic drug pipeline, eye disease treatments
Industry3 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Pre-commercial biotech company generating revenue through licensing agreements. Received up to US$91 million in upfront and milestone payments from Santen Pharmaceutical for CBT-001 licensing in Japan and Southeast Asia. Also receives royalty payments as a percentage of future net sales.

cloudbreakpharma.com
2Milestone Payments
TypeLicensing Royalties
Description

Company receives milestone payments upon achievement of development and regulatory milestones from licensing partners such as Santen Pharmaceutical and Grand Pharmaceutical Group.

cloudbreakpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cloudbreak Pharma is a clinical-stage biotechnology company developing first-in-class and best-in-class ophthalmic drug candidates for chronic eye diseases. Its pipeline includes CBT-001 (multi-kinase inhibitor eye drop for pterygium), CBT-004 (for vascularized pinguecula), CBT-009 (non-aqueous atropine for juvenile myopia), and CBT-199 (pupil-constricting formulation for presbyopia), enabled by proprietary MKI and SFA+ technology platforms. The company monetizes through regional licensing partnerships with pharmaceutical companies for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Pterygium vascularity reduction: -0.8 grade (p<0.001); 68% responder rate (≥1 grade improvement)
+3 more records
Product overview1 text field

Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company developing a pipeline of novel first-in-class and best-in-class ophthalmic drugs. Its portfolio is anchored by two Phase 3-ready assets: CBT-001 (nintedanib-based multi-kinase inhibitor eye drop for pterygium) and CBT-004 (multi-kinase inhibitor eye drop for vascularised pinguecula), alongside CBT-009 (non-aqueous atropine formulation for juvenile myopia, Phase 3) and CBT-199 (pupil-constricting formulation for presbyopia, in development). The pipeline is enabled by two proprietary technology platforms: the MKI (Multi-Kinase Inhibitor) Platform targeting the root pathophysiology of fibrovascular eye diseases, and the SFA+ (Semi-Fluorinated Alkanes+) Platform providing a non-aqueous drug delivery carrier for improved stability and bioavailability.

Product and service3 records
1CBT-001
CategoryOphthalmic Pharmaceuticals
Description

An emulsified nintedanib ophthalmic eye drop formulation (multi-kinase inhibitor) targeting VEGFRs, PDGFRs, and FGFRs for the treatment of pterygium. It inhibits neovascularization and tissue fibrosis, with the potential to become the first FDA-approved drug therapy for pterygium.

2CBT-004
CategoryOphthalmic Pharmaceuticals
Description

A multi-kinase inhibitor eye drop targeting VEGFRs and PDGFRs for the treatment of vascularised pinguecula. It aims to reduce abnormal angiogenesis by blocking VEGF signaling and inhibit fibroblast activation via PDGFR suppression.

3CBT-009
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Santen Pharmaceutical Co., Ltd. (参天制药)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-06
Description

Licensing agreement for CBT-001 (nintedanib eye drops for pterygium treatment). Santen receives rights to develop, manufacture and commercialize CBT-001 in Japan, South Korea, Vietnam, Thailand, Malaysia, Philippines, Singapore, and Indonesia. Cloudbreak receives up to US$91 million in upfront and milestone payments plus double-digit royalties on net sales. Santen is a specialist ophthalmology company with 140+ years of history serving approximately 50 million people in 60+ countries.

cloudbreakpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-17
Description

Strategic cooperation memorandum of understanding signed at Asia Healthcare Summit in Hong Kong. CEVR is established under Hong Kong's InnoHK initiative as a collaboration between Hong Kong Polytechnic University and University of Waterloo, Canada. The partnership aims to pursue further research in ophthalmic science development, aligned with Cloudbreak's CBT-006 clinical pipeline research direction.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-04-01
Description

Commercialization license agreement granting Grand Pharmaceutical Group (00512.HK) exclusive, sublicensable rights with royalty for production and commercialization of CBT-001 in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan region. The license covers the investigational indications of prevention of pterygium growth and reduction of conjunctival congestion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Inheritor of Allergan's ophthalmology franchise (RESTASIS, LUMIGAN, BOTOX). Broad incumbent comparable because Allergan's former leadership now sits in Cloudbreak's C-suite, and Allergan historically dominated the anterior-segment ophthalmic prescription market Cloudbreak is targeting.

TypeBroad incumbent
Description

World's largest dedicated ophthalmology company spanning surgical, vision care, and pharmaceuticals. Broad incumbent with portfolio capabilities that overlap Cloudbreak's surface eye-disease therapeutic focus, providing a benchmark for end-stage commercial scale.

TypeBroad incumbent
Description

Major diversified ophthalmology company across pharmaceuticals, surgical devices, and contact lenses. Broad incumbent with overlapping therapeutic focus on chronic anterior-segment conditions and an established global commercialization footprint.

TypeDirect peer
Description

Clinical-stage ophthalmology biotech focused on micro-dose array print (MAP) drug delivery. Closely comparable in stage, size, and therapeutic focus; Cloudbreak's newly hired CBO Michael Rowe was previously CEO of Eyenovia, evidencing deep familiarity with the comparable's strategy and challenges.

TypeDirect peer
Description

Clinical-stage biotech developing novel small-molecule therapies for ocular and systemic inflammatory diseases. Comparable as a small-cap, pre-commercial, platform-based ophthalmology developer with multiple Phase 2/3 assets in chronic eye conditions.

TypeDirect peer
Description

Clinical-stage ophthalmology biotech focused on small-molecule therapies for refractive and retinal indications. Comparable size and stage, with similar reliance on licensing or strategic transactions to advance pipeline assets in underserved ocular indications.

TypeDirect peer
Description

Clinical and early-commercial ophthalmology biotech developing sustained-release ocular drug delivery using bioerodible Durasert and Yutiq platforms. Directly comparable in targeting chronic anterior- and posterior-segment eye diseases with proprietary delivery platforms.

8Santen Pharmaceutical
TypeBroad incumbent
Description

Japan-headquartered global specialist ophthalmology company and Cloudbreak's licensing partner for CBT-001 across APAC. Direct incumbent comparator: established commercial infrastructure, broad ophthalmic portfolio, and Asia-Pacific regulatory reach that materially exceeds Cloudbreak's.

TypeEmerging player
Description

Clinical-stage gene therapy company targeting ophthalmic diseases (wet AMD, diabetic macular edema). Adjacent emerging player rather than direct competitor (different modality), but comparable in size, stage, and the strategy of pursuing high-unmet-need ocular indications with novel platforms.

TypeDirect peer
Description

Clinical/commercial ophthalmology company developing sustained-release drug formulations (intracameral implants, topical hydrogels). Highly comparable business model of proprietary drug-delivery platforms (akin to Cloudbreak's SFA+) applied to ophthalmic indications with high unmet need.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cloudbreak Pharma

Ophthalmic Pharmaceuticalscloudbreakpharma.com

Cloudbreak Pharma is a clinical-stage ophthalmology biotech developing first-in-class eye drops for pterygium, pinguecula, myopia, and presbyopia using proprietary multi-kinase inhibitor and SFA+ delivery platforms, monetizing via regional licensing with Santen and Grand Pharmaceutical pending FDA approval.

What Cloudbreak Pharma does

Cloudbreak Pharma, Inc. is a clinical-stage ophthalmology biotechnology company founded in 2015 and headquartered in Irvine, California, with a regional office in Hong Kong and a listing on the Hong Kong Stock Exchange (HKEX: 2592). The company is developing a pipeline of first-in-class and best-in-class ophthalmic drugs targeting diseases with no FDA-approved pharmacological therapies, including pterygium, vascularized pinguecula, juvenile myopia, and presbyopia. As of mid-2025 it had four clinical-stage candidates — CBT-001 (nintedanib-based multi-kinase inhibitor eye drop for pterygium, Phase 3), CBT-004 (MKI eye drop for pinguecula, Phase 2 complete with Phase 3 readiness), CBT-009 (non-aqueous atropine for juvenile myopia, Phase 3), and CBT-199 (pupil-constricting formulation for presbyopia) — supported by four pre-clinical programs.

The company's scientific differentiation rests on two proprietary platforms: a Multi-Kinase Inhibitor (MKI) platform that simultaneously targets VEGFR, PDGFR, and FGFR to inhibit the angiogenesis and fibrosis driving pterygium and pinguecula; and a Semi-Fluorinated Alkanes (SFA+) drug-delivery platform providing non-aqueous, preservative-free formulations with improved stability and bioavailability for assets such as CBT-009 and CBT-199. The SFA+ carrier system directly addresses the long-standing stability limitation of aqueous low-dose atropine products.

Cloudbreak is pre-commercial and currently monetizes through regional licensing agreements rather than direct sales. In August 2024 it signed a licensing deal with Santen Pharmaceutical for CBT-001 across Japan and seven other Asia Pacific markets, worth up to US$91 million in upfront and milestone payments plus double-digit royalties on net sales. A 2020 agreement with Grand Pharmaceutical Group grants exclusive Greater China commercialization rights for CBT-001. The company is preparing for direct U.S. commercialization, evidenced by a new U.S. website launched in April 2026, appointment of Michael Rowe as Chief Business Officer in December 2025, and an experienced commercial leadership bench drawn from Allergan, Santen, Pfizer, Bayer, and Eyenovia.

Cloudbreak Pharma firmographics

Firmographics
Name
Cloudbreak Pharma
Legal name
Cloudbreak Pharma, Inc.
Website
https://cloudbreakpharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Cloudbreak Pharma is a clinical-stage ophthalmology biotech developing first-in-class eye drops for pterygium, pinguecula, myopia, and presbyopia using proprietary multi-kinase inhibitor and SFA+ delivery platforms, monetizing via regional licensing with Santen and Grand Pharmaceutical pending FDA approval.
Ownership category
akta.pro rank

Cloudbreak Pharma industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Ophthalmic pharmaceuticals
  • Biotechnology drug development
  • Clinical-stage therapeutics
  • Ophthalmic drug pipeline
  • Eye disease treatments

Where Cloudbreak Pharma is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cloudbreak Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Licensing and Royalty Revenue: Pre-commercial biotech company generating revenue through licensing agreements. Received up to US$91 million in upfront and milestone payments from Santen Pharmaceutical for CBT-001 licensing in Japan and Southeast Asia. Also receives royalty payments as a percentage of future net sales.
  2. Milestone Payments: Company receives milestone payments upon achievement of development and regulatory milestones from licensing partners such as Santen Pharmaceutical and Grand Pharmaceutical Group.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Cloudbreak Pharma product offering

Product offering

Core offering

Cloudbreak Pharma is a clinical-stage biotechnology company developing first-in-class and best-in-class ophthalmic drug candidates for chronic eye diseases. Its pipeline includes CBT-001 (multi-kinase inhibitor eye drop for pterygium), CBT-004 (for vascularized pinguecula), CBT-009 (non-aqueous atropine for juvenile myopia), and CBT-199 (pupil-constricting formulation for presbyopia), enabled by proprietary MKI and SFA+ technology platforms. The company monetizes through regional licensing partnerships with pharmaceutical companies for commercialization.

Product overview

Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company developing a pipeline of novel first-in-class and best-in-class ophthalmic drugs. Its portfolio is anchored by two Phase 3-ready assets: CBT-001 (nintedanib-based multi-kinase inhibitor eye drop for pterygium) and CBT-004 (multi-kinase inhibitor eye drop for vascularised pinguecula), alongside CBT-009 (non-aqueous atropine formulation for juvenile myopia, Phase 3) and CBT-199 (pupil-constricting formulation for presbyopia, in development). The pipeline is enabled by two proprietary technology platforms: the MKI (Multi-Kinase Inhibitor) Platform targeting the root pathophysiology of fibrovascular eye diseases, and the SFA+ (Semi-Fluorinated Alkanes+) Platform providing a non-aqueous drug delivery carrier for improved stability and bioavailability.

Differentiator

Problem solved

Functional benefit

Products and services

  • CBT-001 An emulsified nintedanib ophthalmic eye drop formulation (multi-kinase inhibitor) targeting VEGFRs, PDGFRs, and FGFRs for the treatment of pterygium. It inhibits neovascularization and tissue fibrosis, with the potential to become the first FDA-approved drug therapy for pterygium.
  • CBT-004 A multi-kinase inhibitor eye drop targeting VEGFRs and PDGFRs for the treatment of vascularised pinguecula. It aims to reduce abnormal angiogenesis by blocking VEGF signaling and inhibit fibroblast activation via PDGFR suppression.
  • CBT-009

Quantifiable outcome

  • Pterygium vascularity reduction: -0.8 grade (p<0.001); 68% responder rate (≥1 grade improvement)
  • +3 more outcomes

Companies that use Cloudbreak Pharma

Customer profile

Segments4 records

Ideal customer profiles1 record

Cloudbreak Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Cloudbreak Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Santen Pharmaceutical Co., Ltd. (参天制药)coreOEM/ Whitelabel/ Licensing Partner · 6 August 2024Licensing agreement for CBT-001 (nintedanib eye drops for pterygium treatment). Santen receives rights to develop, manufacture and commercialize CBT-001 in Japan, South Korea, Vietnam, Thailand, Malaysia, Philippines, Singapore, and Indonesia. Cloudbreak receives up to US$91 million in upfront and milestone payments plus double-digit royalties on net sales. Santen is a specialist ophthalmology company with 140+ years of history serving approximately 50 million people in 60+ countries.
  • Centre for Eye and Vision Research Ltd. (CEVR)minorStrategic or Co-development Partner · 17 May 2023Strategic cooperation memorandum of understanding signed at Asia Healthcare Summit in Hong Kong. CEVR is established under Hong Kong's InnoHK initiative as a collaboration between Hong Kong Polytechnic University and University of Waterloo, Canada. The partnership aims to pursue further research in ophthalmic science development, aligned with Cloudbreak's CBT-006 clinical pipeline research direction.
  • Grand Pharmaceutical Group Limited (远大医药)coreOEM/ Whitelabel/ Licensing Partner · 1 April 2020Commercialization license agreement granting Grand Pharmaceutical Group (00512.HK) exclusive, sublicensable rights with royalty for production and commercialization of CBT-001 in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan region. The license covers the investigational indications of prevention of pterygium growth and reduction of conjunctival congestion.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Cloudbreak Pharma competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan Aesthetics / Eye Care): Inheritor of Allergan's ophthalmology franchise (RESTASIS, LUMIGAN, BOTOX). Broad incumbent comparable because Allergan's former leadership now sits in Cloudbreak's C-suite, and Allergan historically dominated the anterior-segment ophthalmic prescription market Cloudbreak is targeting.
  • Alcon: World's largest dedicated ophthalmology company spanning surgical, vision care, and pharmaceuticals. Broad incumbent with portfolio capabilities that overlap Cloudbreak's surface eye-disease therapeutic focus, providing a benchmark for end-stage commercial scale.
  • Bausch + Lomb (Bausch Health): Major diversified ophthalmology company across pharmaceuticals, surgical devices, and contact lenses. Broad incumbent with overlapping therapeutic focus on chronic anterior-segment conditions and an established global commercialization footprint.
  • Santen Pharmaceutical: Japan-headquartered global specialist ophthalmology company and Cloudbreak's licensing partner for CBT-001 across APAC. Direct incumbent comparator: established commercial infrastructure, broad ophthalmic portfolio, and Asia-Pacific regulatory reach that materially exceeds Cloudbreak's.

Direct peers

  • Eyenovia: Clinical-stage ophthalmology biotech focused on micro-dose array print (MAP) drug delivery. Closely comparable in stage, size, and therapeutic focus; Cloudbreak's newly hired CBO Michael Rowe was previously CEO of Eyenovia, evidencing deep familiarity with the comparable's strategy and challenges.
  • Aldeyra Therapeutics: Clinical-stage biotech developing novel small-molecule therapies for ocular and systemic inflammatory diseases. Comparable as a small-cap, pre-commercial, platform-based ophthalmology developer with multiple Phase 2/3 assets in chronic eye conditions.
  • Ocuphire Pharma: Clinical-stage ophthalmology biotech focused on small-molecule therapies for refractive and retinal indications. Comparable size and stage, with similar reliance on licensing or strategic transactions to advance pipeline assets in underserved ocular indications.
  • EyePoint Pharmaceuticals: Clinical and early-commercial ophthalmology biotech developing sustained-release ocular drug delivery using bioerodible Durasert and Yutiq platforms. Directly comparable in targeting chronic anterior- and posterior-segment eye diseases with proprietary delivery platforms.
  • Ocular Therapeutix: Clinical/commercial ophthalmology company developing sustained-release drug formulations (intracameral implants, topical hydrogels). Highly comparable business model of proprietary drug-delivery platforms (akin to Cloudbreak's SFA+) applied to ophthalmic indications with high unmet need.

Emerging players

  • Adverum Biotechnologies: Clinical-stage gene therapy company targeting ophthalmic diseases (wet AMD, diabetic macular edema). Adjacent emerging player rather than direct competitor (different modality), but comparable in size, stage, and the strategy of pursuing high-unmet-need ocular indications with novel platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cloudbreak Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cloudbreak Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Cloudbreak Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cloudbreak Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cloudbreak Pharma

What does Cloudbreak Pharma do?

Cloudbreak Pharma is a clinical-stage biotechnology company developing first-in-class and best-in-class ophthalmic drug candidates for chronic eye diseases. Its pipeline includes CBT-001 (multi-kinase inhibitor eye drop for pterygium), CBT-004 (for vascularized pinguecula), CBT-009 (non-aqueous atropine for juvenile myopia), and CBT-199 (pupil-constricting formulation for presbyopia), enabled by proprietary MKI and SFA+ technology platforms. The company monetizes through regional licensing partnerships with pharmaceutical companies for commercialization.

Is Cloudbreak Pharma a public or private company?

Cloudbreak Pharma is a public company. It is classified as public and is currently operating.

When was Cloudbreak Pharma founded?

Cloudbreak Pharma was founded in 2015. It employs 51 to 100 people.

Where is Cloudbreak Pharma based?

Cloudbreak Pharma is headquartered in Irvine, United States, in the North America region.

How does Cloudbreak Pharma make money?

Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are milestone Payments.

Who are Cloudbreak Pharma's main competitors?

Broad incumbents on record are AbbVie (Allergan Aesthetics / Eye Care), Alcon, Bausch + Lomb (Bausch Health) and Santen Pharmaceutical. Direct peers are Eyenovia, Aldeyra Therapeutics, Ocuphire Pharma, EyePoint Pharmaceuticals and Ocular Therapeutix. Adverum Biotechnologies is listed as an emerging player.

Does Cloudbreak Pharma have an API?

No public API is recorded for Cloudbreak Pharma.

What industry is Cloudbreak Pharma in?

Cloudbreak Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialCloudbreak Pharma Inc. (02592.HK) Unveils Phase III Topline Data For CBT-001: The First Randomized, Double-Blind Validation Of A Drug Treatment For PterygiumCloudbreak Pharma released topline data from its Phase III trial of CBT-001 for pterygium, with both co-primary endpoints met. The drug reduced conjunctival hyperemia and lesion length significantly versus placebo, with effects sustained through 12 months. The company will now discuss regulatory pathways with the FDA and NMPA.ACN NewswireCloudbreak Pharma Inc. (02592.HK) Unveils Phase III Topline Data for CBT-001: The First Randomized, Double-Blind Validation of a Drug Treatment for PterygiumCloudbreak Pharma released topline data from its Phase III trial of CBT-001 for pterygium, with both co-primary endpoints met. The drug reduced conjunctival hyperemia and lesion length by about 10% versus placebo at Month 12. The company will now discuss regulatory pathways with the FDA and NMPA.The Pharma LetterCloudbreak’s eye drop meets Phase III endpoints in pterygium, as shares remain suspendedCloudbreak Pharma's multi-kinase inhibitor eye drop CBT-001 met its primary endpoints in a Phase III trial for pterygium. The company plans to meet the FDA as soon as practicable to review results and discuss next steps.FierceBiotechCloudbreak posts phase 3 eye disease win amid IPO stormCloudbreak Pharma reported statistically significant improvements on both primary endpoints of its phase 3 trial for CBT-001, an eye drop for pterygium. The drug showed about 10% treatment-versus-vehicle benefit, with superficial punctate keratitis as the most common adverse event. The company plans to meet the FDA and may start a second phase 3 trial in 2026.TradingViewCloudbreak Pharma Reports Significant Phase 3 CBT-001 ResultsCloudbreak Pharma reported Phase 3 topline results for CBT-001, showing both doses significantly improved conjunctival hyperemia at Month 3 and prevented pterygium lesion progression at Month 12 versus vehicle (p<0.001). The company plans to meet with the FDA to discuss next steps, with additional analyses ongoing.YicaiglobalHong Kong Regulator Freezes Record USD594 Million of Assets in Suspected IPO Fraud CasesHong Kong's Securities and Futures Commission froze HKD4.66 billion (USD594 million) in assets linked to two syndicates suspected of IPO fraud in three cases. The frozen assets cover 31 brokerages, with trading halted for Baicha Baidao, Cloudbreak Pharma, and Tianju Dihe. The SFC said the groups may have diverted IPO proceeds into financial products before returning them to investors.AInvestCloudbreak Pharma: Pipeline Progress Won't Save a Suspended StockHong Kong's SFC suspended trading in Cloudbreak Pharma on September 10, 2026, citing concerns over a rigged IPO. The company's cash runway has shrunk to about five months at a US$52 million annual burn, with Phase III trials complete and topline results pending. No entry point exists until the suspension lifts.DealStreetAsiaAsia's private markets are resetting around capital and liquidityAsia's private markets are entering a new cycle with tighter capital discipline, as the Asia PE-VC Summit 2026 explores liquidity and capital sources. Hong Kong's Five-Year Plan sets green targets and IPO scrutiny, while India's PE exits totaled $13.52 billion this year. Private credit is gaining traction among Asian institutional investors.South China Morning PostTighter scrutiny of Hong Kong IPOs could slow deal flow, analysts sayHong Kong and mainland China regulators are tightening scrutiny on IPOs, with the CSRC asking nine pre-approved firms for supplementary materials and the SFC suspending Cloudbreak Pharma's trading. Analysts say this could slow deal flow but not reduce underlying demand.DevdiscourseIntensifying Scrutiny: Hong Kong's Regulatory Clampdown on Booming Share SalesThe Hong Kong Securities and Futures Commission is intensifying oversight of investment banks amid rising share sales, primarily from Chinese tech companies. The SFC is scrutinizing misconduct such as fund misuse and artificial demand, and halted Cloudbreak Pharma's trading. It also investigates insider trading linked to some brokers.